You are here

Global Stem Cell Therapy Contract Manufacturing Market Research 2019-2030: Source of Stem Cells, Types of Stem Cells, Size of Contract Service Provider Company, Scale of Operation, Key Regions

DUBLIN, Dec. 3, 2019 /PRNewswire/ -- The "Stem Cell Therapy Contract Manufacturing Market, 2019-2030" report has been added to's offering.

The Stem Cell Therapies Contract Manufacturing Market, 2019 - 2030 report features an extensive study on contract service providers engaged in the development and manufacturing of stem cell therapies. The study features in-depth analyses, highlighting the capabilities of various stem cell therapy CMOs.

Advances in the fields of cell biology and regenerative medicine have led to the development of a variety of stem cell-based therapies for many cardiovascular, oncological, metabolic and musculoskeletal disorders. Driven by the revenues generated from stem cell therapies, the regenerative medicine market is anticipated to generate revenues worth USD 100 billion by 2030. With a promising pipeline of over 200 stem cell therapy candidates, it has become essential for developers to scale up the production of such therapeutic interventions. Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies.

As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.

According to a recent Nice Insight CDMO survey, about 55% of 700 respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development requirements. Considering the prevalent trends, we believe that the stem cell therapy manufacturing market is poised to grow at a steady pace, driven by a robust pipeline of therapy candidates and technological advances aimed at mitigating challenges posed by conventional methods of production. Amidst tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry.

One of the key objectives of the report was to estimate the future size of the market. Based on parameters, such as increase in number of clinical studies, target patient population, anticipated adoption of stem cell therapies and expected variation in manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the period 2019-2030.

Amongst other elements, the report includes:

  • A detailed review of the contract manufacturing landscape for stem cell therapies, featuring a comprehensive list of active CMOs and analysis based on a number of parameters, such as year of establishment, company size, geographical location, number of stem cell therapy manufacturing facilities, source of stem cells (allogenic and autologous), types of services offered (culture development, stem cell identification / validation, stem cell banking, cryopreservation, logistics, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), types of stem cells (adult, embryonic and induced pluripotent) and therapeutic area (oncology and non-oncology).
  • An elaborate discussion of the various guidelines laid down by regulatory bodies related to stem cells and other cell-based therapies across various geographies, such as the North America (primarily the US), Europe and other regions.
  • Elaborate profiles of the key players based in North America, Europe and Asia-Pacific that have a diverse range of capabilities for the development, manufacturing and packaging of stem cell therapies. Each profile includes an overview of the company, its financial performance (if available), information on service portfolio, stem cell therapy manufacturing facilities, and details on partnerships, recent developments and an informed future outlook.
  • An analysis of the recent collaborations (signed since 2015) focused on the contract manufacturing of stem cell therapies, based on various parameters, such as year of agreement, type of agreement, scale of operation, source of stem cells used, types of stem cells and location of companies entering the partnership.
  • An informed estimate of the annual demand for stem cell therapies in terms of area (in square feet) dedicated to stem-cell related operations, based on various parameters, such as target patient population, price of the therapy, dosing frequency and dose strength.
  • A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized and large CMOs) in the market, based on data gathered via secondary and primary research. It also provides the distribution of global stem cell therapy manufacturing capacity by company size (small-sized, mid-sized and large), and geography (North America, Europe and Asia-Pacific) and scale of operation (preclinical / clinical and commercial).
  • A detailed analysis to understand the relationship between the demand and supply in this field, comparing the presence of stem cell therapy developers and the availability / capability of contract manufacturers across different geographies.
  • An analysis to identify the key performance indicators for service providers active in the domain, based on the information gathered via secondary research and primary research.

In order to provide a detailed future outlook, our projections have been segmented on the basis of:

  • [A] source of stem cells (autologous and allogenic)
  • [B] types of stem cells (adult, embryonic and induced pluripotent)
  • [C] size of contract service provider company (small-sized, mid-sized and large)
  • [D] scale of operation (preclinical, clinical and commercial)
  • [E] key geographical regions (North America, Europe and Asia and rest of the world)

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Regulatory Landscape

6. Stem Cell Therapy Contract Manufacturers In North America

7. Stem Cell Therapy Contract Manufacturers In Europe And Asia-Pacific

8. Partnerships And Collaboration

9. Contract Manufacturing Opportunity Assessment

10. Capacity Analysis

11. Demand Analysis

12. Market Forecast

13. Key Performance Indicators

14. Concluding Remark

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List Of Companies And Organizations

  • 3P Biopharmaceuticals
  • AbbVie
  • Accellta
  • Adaptimmune
  • Advancecells
  • Advanced Cell Technology
  • Aegle Therapeutics
  • Aelan Cell Technologies
  • AGC
  • Ajinomoto
  • Ajinomoto Kohjin Bio
  • AllCells
  • Allele Biotechnology & Pharmaceuticals
  • Alpine BioTherapeutics
  • American CryoStem
  • Anagenesis Biotechnologies
  • Andalusian Initiative for Advanced Therapies
  • Angel Biotechnology
  • Anterogen
  • apceth Biopharma
  • Aspire Health Science
  • Astellas Pharma
  • Asterias Biotherapeutics
  • AstraZeneca
  • Athersys
  • Atlantic Bio GMP
  • Avid Bioservices
  • Axcelead Drug Discovery Partners
  • Axiogenesis
  • Baxter International
  • Bellicum Pharmaceuticals
  • Ben-Gurion University of the Negev
  • Bio Elpida
  • BioCardia
  • Bioinova
  • BioIVT
  • BioLife Cell Bank
  • Biological and Cellular GMP Manufacturing Facility, City of Hope
  • BioNTech IMFS
  • BioRestorative Therapies
  • bluebird bio
  • BlueRock Therapeutics
  • Bone Therapeutics
  • BrainStorm Cell Therapeutics
  • Caladrius Biosciences
  • Capicor Therapeutics
  • CardioCell
  • CardioCreate
  • Case Western Reserve University School of Medicine
  • Cell and Gene Therapy Catapult
  • Cell Cure Neurosciences
  • Cell Source
  • Cell Tech Pharmed
  • Cell Therapies
  • Cell Therapy and Regenerative Medicine, University of Utah
  • Cell Therapy Manufacturing Cooperative Research Centre
  • Cellect Biotechnology
  • Cellerant Therapeutics
  • CellProthera
  • Cells for Sight, Stem Cell Therapy Research Unit, University College London
  • Cellular Biomedicine Group
  • Cellular Therapy Core, University of Texas
  • Celther Polska
  • Center for Biomedical Engineering and Advanced Manufacturing, McMaster University
  • Center for Cell and Gene Therapy, Baylor College of Medicine
  • Center for Molecular Medicine Cologne
  • Center for Specialised Care & Research
  • Centre for Cell and Vector Production (CCVP)
  • Centre of Excellence for Cellular Therapy
  • Chiesi Farmaceutici
  • Clean Cells
  • ClinImmune Labs
  • CMC Biologics
  • Cognate BioServices
  • Colorado Center for Reproductive Medicine (CCRM)
  • Cook MyoSite
  • Corestem
  • Creative Medical Technology Holdings
  • Cryosite
  • Cryoviva Biotech
  • CSL Behring
  • Cynata Therapeutics
  • Cytopeutics
  • Cytori Therapeutics
  • Daiichi Sankyo
  • Dendreon
  • Digilab
  • DiscGenics
  • Duke University School of Medicine
  • Eli Lilly
  • Emory Personalized Immunotherapy Core
  • ExCellThera
  • Exopharm
  • Fate Therapeutics
  • Fibrocell
  • Florey Institute of Neuroscience and Mental Health
  • Fraunhofer Institute for Cell Therapy and Immunology
  • FUJIFILM Cellular Dynamics
  • FUJIFILM Irvine Scientific
  • Gamida Cell
  • Gates Biomanufacturing Facility
  • GE Healthcare
  • GenCure
  • Gene and Cell Therapy Lab, Institute of Translational Health Sciences
  • Genxbio
  • Genzyme Biosurgery
  • Global Cell Med
  • Global Stem Cells and Regenerative Medicine Acceleration Center
  • Grace Century
  • Guy's and St Thomas' Facility
  • Gwo XI Stem Cell Applied Technology
  • Harvard Stem Cell Institute, Harvard University
  • Healios
  • Helocyte
  • HemoGenyx Pharmaceuticals
  • Hemostemix
  • Histocell
  • Histogen
  • Holostem Terapie Avanzate
  • Ichor Therapeutics
  • ID Pharma
  • Institute of Liver & Biliary Sciences
  • Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami
  • International Stem Cell Corporation
  • iPS Academia Japan
  • IQVIA Stem Cell Center
  • Japan Tissue Engineering
  • Japanese Society for Regenerative Medicine
  • John Goldman Centre for Cellular Therapy
  • Johnson & Johnson
  • Kadimastem
  • Kangstem Biotech
  • KBI Biopharma
  • Kohjin-Bio
  • Kolon Life Sciences
  • Kyoto University
  • Kyushu University
  • Laboratory for Cell and Gene Medicine, University of Stanford
  • Life Stem Genetics
  • Lifecells
  • LifeSouth Community Blood Centers
  • Living Cell Technologies
  • Longeveron
  • Lonza
  • Magenta Therapeutics
  • MaSTherCell
  • Medeor Therapeutics
  • Medipost
  • Merck
  • Mesoblast
  • Michael J Fox Foundation for Parkinson's Research
  • Molecular and Cellular Therapeutics, University of Minnesota
  • Moraga Biotechnology
  • Morphogenesis
  • Nanion Technologies
  • National Eye Institute
  • Nature Cell
  • Neovii
  • Nestl Institute of Health Sciences
  • Neuralstem
  • NeuroGen Brain & Spine Institute
  • NeuroGeneration
  • New York Blood Center
  • NHS Blood and Transplant (NHSBT)
  • NIHR GOSH Biomedical Research Centre
  • Nikon CeLL innovation
  • Nohla Therapeutics
  • Novadip Biosciences
  • Novartis
  • Ocata Therapeutics
  • Octane Biotech
  • OhioHealth
  • OiDE BetaRevive
  • Orchard Therapeutics
  • Organogenesis
  • Orgenesis
  • Orisis Therapeutics
  • Personalized Stem Cells
  • Pfizer
  • PharmaCell
  • Pharmicell
  • Philip S Orsino Facility for Cell Therapy, Princess Margaret Hospital
  • Pluristem Therapeutics
  • Progenitor Cell Therapy (PCT)
  • Promethera Biosciences
  • Protide Pharmaceuticals
  • Provia Laboratories
  • Rayne Cell Therapy Suite, King's College London
  • Regeneris Medical
  • Regeneus
  • ReNeuron
  • Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation
  • Roche
  • ROHTO Pharmaceutical
  • RoosterBio
  • RoslinCT
  • Roswell Park Cancer Institute
  • Royal Free Hospital
  • Samsung BioLogics
  • SanBio
  • Saneron CCEL Therapeutics
  • Sangamo Therapeutics
  • S-Biomedic
  • Sclnow Biotechnology
  • SCM Lifescience
  • Scottish National Blood Transfusion Service (SNBTS)
  • Sentien Biotechnologies
  • SeouLin Bioscience
  • Shanghai Biotechnology
  • Sistemic
  • SSM Health Cardinal Glennon Children's Hospital
  • Stem Cell Theranostics
  • Stem Cells Arabia
  • StemBioSys
  • STEMCELL Technologies
  • Stemedica Cell Technologies
  • StemGenn Therapeutics
  • Steminent Biotherapeutics
  • Stemline Therapeutics
  • Stemmatters
  • StemoniX
  • Stempeutics Research
  • Taiga Biotechnologies
  • Taiwan Bio Therapeutics
  • Takara Bio
  • Takeda Pharmaceutical
  • Terumo
  • Theracell
  • Tianhe Stem Cell Biotechnologies
  • Tianjin Ever Union Biotechnology
  • TiGenix
  • Tissue Genesis
  • TreeFrog Therapeutics
  • U.S. Stem Cell
  • UC Davis GMP Laboratory
  • UC Irvine Medical Center
  • UCI Beall Applied Innovation
  • Universal Cells
  • University Hospitals Case Medical Center
  • University of California
  • University of Manchester
  • University of Newcastle
  • Upstate Stem Cell cGMP Facility, University of Rochester
  • Vecura, Karolinska University Hospital
  • Vericel
  • ViaCyte
  • Viscofan
  • Viscofan BioEngineering
  • Vor Biopharma
  • Waisman Biomanufacturing
  • Worldwide Clinical Trials
  • WuXi Advanced Therapies
  • Xcelthera
  • Xellbiogene
  • YposKesi

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:

SOURCE Research and Markets